Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 16/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 15/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 13/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 10/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 9/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 7/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 7/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 7/20 | 1.00 |
| ▸ | HDAC5 | Q9UQL6 | 7/20 | 1.00 |
| ▸ | NCOR2 | Q9Y618 | 7/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29921577 | 1.00 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC4HDAC10 | |
| SCHEMBL1063954 | 1.00 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC4HDAC10 | |
| SCHEMBL30029834 | 1.00 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC4HDAC10 | |
| SCHEMBL1902019 | 0.98 | HDAC1 (0.97) | HDAC1HDAC3HDAC2HDAC4HDAC10 | |
| SCHEMBL29736959 | 0.94 | HDAC1 (0.89) | HDAC1HDAC3HDAC2HDAC4HDAC10 | |
| SCHEMBL8241153 | 0.92 | HDAC3 (1.00) | HDAC1HDAC3HDAC2HDAC4HDAC10 | |
| Benzamide SCHEMBL17559260 | 0.92 | HDAC1 (0.84) | HDAC1HDAC3HDAC2HDAC4HDAC10 | |
| SCHEMBL16016612 | 0.91 | HDAC1 (0.84) | HDAC1HDAC3HDAC2HDAC4HDAC10 | |
| SCHEMBL12125319 | 0.91 | HDAC1 (0.83) | HDAC1HDAC3HDAC2HDAC4HDAC10 | |
| SCHEMBL31635257 | 0.91 | HDAC4 (0.85) | HDAC1HDAC3HDAC2HDAC4HDAC10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 609 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106917-A1 | EDIBLE TRANSMUCOSAL DRUG DELIVERY METHOD USING AN INTERMEDIATE CAPSULE AS A TEMPORARY VESSEL | BioPhysics Pharma, Inc. (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | TRAILHEAD BIOSYSTEMS INC (US) | 2026-05-07 | — | — | US | claimed |
| US-12605345-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2026-04-21 | — | — | US | claimed |
| EP-4720316-A2 | NON-VIRAL CELL ENGINEERING | Arsenal Biosciences, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| US-12582635-B2 | Compositions and methods for treating cancer with atypical BRAF mutations | BIOMED VALLEY DISCOVERIES, INC. (US) | 2026-03-24 | — | — | US | claimed |
| US-12496357-B2 | Compositions and methods for treating sickle cell disease | YALE UNIVERSITY (US) | 2025-12-16 | — | — | US | claimed |
| US-20250268841-A1 | Trans-Epithelial Membrane Drug Delivery System | Masiz, John J. (US) | 2025-08-28 | — | — | US | claimed |
| US-20250188422-A1 | INDUCED TOTIPOTENT POTENTIAL STEM CELLS, METHODS OF MAKING AND USING | PEKING UNIVERSITY (CN) | 2025-06-12 | — | — | US | claimed |
| US-20250144056-A1 | ANTIMICROBIAL HOST DEFENSE PEPTIDE-INDUCING COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF | BOARD OF REGENTS FOR THE OKLAHOMA AGRICULTURAL AND MECH COLLEGES (US) | 2025-05-08 | — | — | US | claimed |
| WO-2025085598-A2 | PERSONALIZED REGENERATIVE CELLS | IMMORTA BIO, INC. (US) | 2025-04-24 | — | — | WO | claimed |
| US-9387263-B2 | RbAp48 transgenic mice for drug discovery in age-related memory decline | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-07-12 | — | — | US | claimed |
| US-9000031-B2 | Thioxanthone-based autophagy inhibitor therapies to treat cancer | SPECTRUM PHARMACEUTICALS, INC. (US) | 2015-04-07 | — | — | US | claimed |
| US-20140294798-A1 | RbAp48 TRANSGENIC MICE FOR DRUG DISCOVERY IN AGE-RELATED MEMORY DECLINE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-10-02 | — | — | US | claimed |
| US-20140235649-A1 | USE OF PHOSPHATASE INHIBITORS OR HISTONE DEACETYLASE INHIBITORS TO TREAT DISEASES CHARACTERIZED BY LOSS OF PROTEIN FUNCTION | LIXTE BIOTECHNOLOGY, INC. (US) | 2014-08-21 | — | — | US | claimed |
| US-8524762-B2 | Thioxanthone-based autophagy inhibitor therapies to treat cancer | SPECTRUM PHARMACEUTICALS, INC. (US) | 2013-09-03 | — | — | US | claimed |
| WO-2013022715-A2 | PBAP48 TRANSGENIC MICE FOR DRUG DISCOVERY IN AGE-RELATED MEMORY DECLINE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2013-02-14 | — | — | WO | claimed |
| EP-2544673-A1 | THIOXANTHONE-BASED AUTOPHAGY INHIBITOR THERAPIES TO TREAT CANCER | Spectrum Pharmaceuticals, Inc. (US) | 2013-01-16 | — | — | EP | claimed |
| CN-102858328-A | Thioxanthone-based autophagy inhibitor therapy for the treatment of cancer | SPECTRUM PHARMACEUTICALS INC | 2013-01-02 | — | — | CN | claimed |
| US-20110275696-A1 | Thioxanthone-Based Autophagy Inhibitor Therapies to Treat Cancer | SPECTRUM PHARMACEUTICALS, INC. | 2011-11-10 | — | — | US | claimed |
| WO-2011112623-A1 | THIOXANTHONE-BASED AUTOPHAGY INHIBITOR THERAPIES TO TREAT CANCER | SPECTRUM PHARMACEUTICALS, INC. (US) | 2011-09-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235649-A1 | USE OF PHOSPHATASE INHIBITORS OR HISTONE DEACETYLASE INHIBITORS TO TREAT DISEASES CHARACTERIZED BY LOSS OF PROTEIN FUNCTION | HDAC1, PPP3CA, PPM1A | HDAC1 1/4885HDAC3 36/4885HDAC2 5/4885 |
| US-12496357-B2 | Compositions and methods for treating sickle cell disease | HBB, HBG1, HBZ | HDAC1 4862/4885HDAC3 4845/4885HDAC2 4881/4885 |
| US-12582635-B2 | Compositions and methods for treating cancer with atypical BRAF mutations | BRAF, SRMS, MAPK3 | HDAC1 3880/4885HDAC3 2618/4885HDAC2 4179/4885 |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | WNT3A, GSK3B, GSK3A | HDAC1 71/4885HDAC3 97/4885HDAC2 432/4885 |
| US-20110275696-A1 | Thioxanthone-Based Autophagy Inhibitor Therapies to Treat Cancer | ATG7, BECN1, SQSTM1 | HDAC1 464/4885HDAC3 418/4885HDAC2 929/4885 |
| US-12605345-B2 | Transdermal drug delivery system | FABP2, VEGFA, CUTA | HDAC1 2024/4885HDAC3 2450/4885HDAC2 2101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.